Saja Mohammed Mohsen¹* and Abdulla Hassan Abdulla²

¹Middle Technical University (MTU), Baquba Technical Institute, Diyala, Iraq

*Corresponding Author: Saja Mohammed Mohsen, Middle Technical University (MTU), Baquba Technical Institute, Diyala, Iraq.

Received: March 13, 2023; Published: March 20, 2023

Abstract

One of the main viruses that affect people, the Coronavirus, primarily targets the respiratory system. Animals could also be infected by Coronaviruses causing a group of respiratory and gastrointestinal severe diseases. After severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third epidemic coronavirus. SARS-CoV-2 causes Coronavirus Disease 2019 or what so called (COVID-19). Since its first confirmation in December 2019, the spreading of COVID-19 has generated a great interest in all the world. Patients who are severely infected with COVID-19 are susceptible to hyper inflammation (HI), that accompanied biomarkers (BMs) could be useful for risk stratification (RS).

Aim and Objective of the Study: The aim of the presented study is to identify some BMs including: Interleukin-6 (IL)-6, Lactate Dehydrogenase Hormone (LDH), D-dimer, Procalcitonin (PCT), Ferritin, and C-reactive protein (CRP), in patients infected with SARS-CoV-2.

Materials and Methods: Serum samples were taken from patients in Diyala Governorate-Iraq during the period of January to April 2021. After detection of the virus through using of real time-PCR technique, the level of the BMs in study groups have been measured.

Results: The current study revealed highly significant relationship between some of the studied BMs in the mean concentrations in the serum of the patients and control group.

Conclusion: The studied BMs have been accompanied with poor outcomes. They could be the main concerns for RS models in testing of severe COVID-19 (S-COVID-19) and guiding the appropriate clinical care.

Keywords: Coronavirus; IL-6; CRP; Ferritin; D-dimer; PCT

References

1. Chen Y., et al. “Emerging coronaviruses: Genome structure, replication, and pathogenesis”. Journal of Medical Virology 92 (2020): 418-423.
2. Hoek L., et al. “Identification of a new human coronavirus”. Nature Medicine 10 (2004): 368-373.
3. Gralinski LE and Menachery VD. “Return of the coronavirus: 2019-nCoV”. Viruses 12 (2020).
4. Ciaccio Marcello and Agnello Luisa. "Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)". Diagnosis4 (2020): 365-372.
5. Mao L., et al. “Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China”. JAMA Neurology (2020).
6. Guan W., et al. “China Medical Treatment Expert Group for Covid-19”. Clinical Characteristics of Coronavirus Disease (2019).
7. Netland J., et al. “Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2”. Journal of Virology15 (2008): 7264-7275.
8. Baig AM., et al. “Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms”. ACS Chemical Neuroscience7 (2020): 995-998.
9. “Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies Alzforum: Alzforum” (2020).
10. Pranata R., et al. “Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis”. Postgraduate Medical Journal (2020): postgradmedj-2020-137884.
11. Huang I., et al. “Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - a systematic review, meta-analysis, and metaregression: diabetes and COVID-19”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 14 (2020): 395-403.
12. Pranata R., et al. “Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19 - systematic review, meta-analysis, and meta-regression”. Journal of Stroke and Cerebrovascular Diseases 29 (2020): 104949.
13. Huang I and Pranata R. “Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis”. Journal of Intensive Care 8 (2020): 36.
14. Mehta P., et al. “COVID19: consider cytokine storm syndromes and immunosuppression”. Lancet 395 (2020): 1033-1034.
15. Ciaccio M and Agnello L. “Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)”. Diagnosis (Berl).4 (2020): 365-372.
16. Lippi G and Plebani M. “The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks”. Clinical Chemistry and Laboratory Medicine 58 (2020): 1063-1069.
17. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine (2020).
18. Agnello L., et al. “Presepsin and midregionalproadrenomedullin in pediatric oncologic patients with febrile neutropenia”. Lab Med (2020).
19. Zaninotto M., et al. “Presepsin in risk stratification of SARS-CoV-2 patients”. Clinica Chimica Acta 507 (2020): 161-163.
20. Siddiqi HK and Mehra MR. “COVID-19 illness in native and immunosuppressed states: a clinical therapeutic staging proposal”. The Journal of Heart and Lung Transplantation 39 (2020): 405-407.
21. Zhang W., et al. “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID19): the experience of clinical immunologists from China”. Clinical Immunology 214 (2020): 108393.
22. Huang I., et al. “C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis”. Therapeutic Advances in Respiratory Disease 14 (2020): 1753466620937175.

Citation

Citation: Saja Mohammed Mohsen and Abdulla Hassan Abdulla. “The Role of Some Biomarkers for Diagnosis of Coronavirus Infection in Diyala Province". Acta Scientific Microbiology 6.4 (2023): 78-82.

Copyright

Copyright: © 2022 Saja Mohammed Mohsen and Abdulla Hassan Abdulla. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.